Prophylactic rivaroxaban improves clinical outcomes in discharged COVID-19 patients
10 Sep 2021
byAudrey Abella
In individuals who were discharged following hospitalization due to COVID-19, thromboprophylaxis with the novel oral anticoagulant rivaroxaban for 35 days led to improved clinical outcomes without increased bleeding compared with no anticoagulation post-discharge, according to findings from the MICHELLE* trial.